| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
The primary reported target of Tangshenoside I is α-glucosidase, an enzyme responsible for the hydrolysis of carbohydrate glycosidic bonds, though the inhibition is weak (IC50 = 1.4 mM). The compound may also be related to the hematopoietic and immunologic functions of Codonopsis Radix. Its neuroprotective, antioxidant, and anti-inflammatory activities suggest interactions with pathways involved in oxidative stress, inflammation, and neuronal survival. However, the exact molecular targets are not fully characterized.
|
|---|---|
| ln Vitro |
In vitro, Tangshenoside I exhibits weak α-glucosidase inhibitory activity with an IC50 of 1.4 mM. The compound shows neuroprotective, antioxidant, and anti-inflammatory activities in cell-based assays. It may modulate immune responses. These activities suggest potential for studying various pharmacological effects, though the weak α-glucosidase inhibition indicates that this may not be the primary mechanism of action. Specific IC50 values for other activities are not detailed in the available literature.
|
| ln Vivo |
Specific in vivo data for Tangshenoside I are limited. The compound has been studied for its potential to enhance cognitive function, protect neurons from oxidative damage, and modulate immune responses. Given its isolation from Codonopsis pilosula, which is traditionally used for hematopoietic and immunologic functions, Tangshenoside I may contribute to the in vivo efficacy of the plant extract. However, studies on the isolated compound in animal models are not detailed.
|
| Enzyme Assay |
The α-glucosidase inhibitory activity is assessed using a colorimetric enzyme assay. α-Glucosidase enzyme is incubated with the substrate p-nitrophenyl-α-D-glucopyranoside (pNPG) and various concentrations of Tangshenoside I. The release of p-nitrophenol is measured spectrophotometrically at 405 nm, and IC50 values are calculated from dose-response curves. For neuroprotective studies, neuronal cells are treated with the compound and exposed to oxidative stress or neurotoxic agents, with cell viability measured by MTT or similar assays.
|
| Cell Assay |
For cellular studies, neuronal cell lines (e.g., SH-SY5Y, PC12) or immune cells are cultured in appropriate media. Cells are treated with Tangshenoside I at various concentrations (e.g., 0.1-100 μM) for 24-72 hours. Cell viability is assessed using MTT or similar assays. For neuroprotection studies, oxidative stress is induced using H₂O₂ or glutamate, and cell death is measured. ROS levels are measured using DCFH-DA. Inflammatory cytokine levels are measured by ELISA. The compound is typically dissolved in DMSO and diluted in culture media.
|
| Animal Protocol |
In vivo studies for Tangshenoside I would be conducted in appropriate animal models. For neuroprotection studies, models of neurodegeneration (e.g., MPTP, 6-OHDA, or Aβ-induced toxicity) would be used. For cognitive function studies, behavioral tests such as the Morris water maze or novel object recognition would be employed. For immunomodulation studies, models of immune activation or suppression would be used. The compound would be administered via oral gavage or intraperitoneal injection. However, specific published protocols are not available.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Tangshenoside I are not reported. As a glycoside, the compound is expected to have limited oral bioavailability due to poor membrane permeability and extensive intestinal metabolism. Pharmacokinetic studies would be required to determine parameters such as half-life, Cmax, and bioavailability. The compound is typically stored as a powder at -20°C and protected from light.
|
| Toxicity/Toxicokinetics |
Toxicological data for Tangshenoside I are limited. As a natural product from Codonopsis pilosula, which has a long history of use in traditional Chinese medicine, the compound is generally considered to have a moderate safety profile. However, comprehensive toxicology studies including acute, subchronic, and genotoxicity assessments have not been reported. The compound should be handled with appropriate safety precautions in laboratory settings.
|
| References | |
| Additional Infomation |
Tangshenoside I is a natural product from Codonopsis pilosula that exhibits weak α-glucosidase inhibitory activity (IC50 = 1.4 mM). It has neuroprotective, antioxidant, anti-inflammatory, and immunomodulatory activities and may be related to the hematopoietic and immunologic functions of Codonopsis Radix. No clinical trials exist. For research use only.
|
| Molecular Formula |
C29H42O18
|
|---|---|
| Molecular Weight |
678.6330
|
| Exact Mass |
678.237
|
| CAS # |
117278-74-7
|
| PubChem CID |
6441191
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.55g/cm3
|
| Boiling Point |
993.4ºC at 760mmHg
|
| Flash Point |
316.4ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.629
|
| LogP |
-2.6
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
47
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
CC(CC(=O)O)(CC(=O)OC/C=C/C1=CC(=C(C(=C1)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O
|
| InChi Key |
ABKPQICIFGNRAA-YCRPTBBLSA-N
|
| InChi Code |
InChI=1S/C29H42O18/c1-29(9-18(32)33,47-28-25(40)23(38)21(36)17(12-31)45-28)10-19(34)43-6-4-5-13-7-14(41-2)26(15(8-13)42-3)46-27-24(39)22(37)20(35)16(11-30)44-27/h4-5,7-8,16-17,20-25,27-28,30-31,35-40H,6,9-12H2,1-3H3,(H,32,33)/b5-4+/t16-,17-,20-,21-,22+,23+,24-,25-,27+,28+,29?/m1/s1
|
| Chemical Name |
5-[(E)-3-[3,5-dimethoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-enoxy]-3-methyl-5-oxo-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoic acid
|
| Synonyms |
Tangshenoside I
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~25 mg/mL (~36.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4736 mL | 7.3678 mL | 14.7356 mL | |
| 5 mM | 0.2947 mL | 1.4736 mL | 2.9471 mL | |
| 10 mM | 0.1474 mL | 0.7368 mL | 1.4736 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
